Alkermes plc
General ticker "ALKS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.0B (TTM average)
Alkermes plc follows the US Stock Market performance with the rate: 8.0%.
Estimated limits based on current volatility of 1.6%: low 29.13$, high 30.07$
Factors to consider:
- Total employees count: 1800 as of 2024
- US accounted for 90.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Regulatory and compliance, Labor/talent shortage/retention, Pandemic risks, Litigation risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [21.61$, 34.83$]
- 2025-12-31 to 2026-12-31 estimated range: [22.65$, 36.36$]
Financial Metrics affecting the ALKS estimates:
- Positive: with PPE of 10.2 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 27.00 > 18.64
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 8.99
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.33 > 6.04
- Positive: Shareholder equity ratio, % of 71.27 > 63.39
- Positive: Interest expense per share per price, % of 0.46 <= 0.79
- Positive: Inventory ratio change, % of 0.50 <= 0.84
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: Investing cash flow per share per price, % of -2.28 <= -0.66
Short-term ALKS quotes
Long-term ALKS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,111.80MM | $1,663.40MM | $1,557.63MM |
| Operating Expenses | $1,254.06MM | $1,249.28MM | $1,137.00MM |
| Operating Income | $-142.26MM | $414.12MM | $420.64MM |
| Non-Operating Income | $-25.04MM | $7.40MM | $23.11MM |
| Interest Expense | $13.04MM | $23.03MM | $22.58MM |
| R&D Expense | $393.84MM | $270.81MM | $245.33MM |
| Income(Loss) | $-167.30MM | $421.52MM | $443.75MM |
| Taxes | $-9.04MM | $-97.64MM | $71.61MM |
| Other Income(Loss) | $0.00MM | $-163.40MM | $-5.07MM |
| Profit(Loss)* | $-283.38MM | $192.36MM | $362.00MM |
| Stockholders Equity | $1,043.75MM | $1,202.69MM | $1,464.98MM |
| Inventory | $181.42MM | $186.41MM | $182.89MM |
| Assets | $1,963.98MM | $2,136.22MM | $2,055.57MM |
| Operating Cash Flow | $21.04MM | $401.35MM | $439.12MM |
| Capital expenditure | $38.26MM | $48.05MM | $33.48MM |
| Investing Cash Flow | $-64.54MM | $53.36MM | $-111.31MM |
| Financing Cash Flow | $-1.57MM | $-289.71MM | $-494.14MM |
| Earnings Per Share** | $-1.73 | $1.16 | $2.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.